Quest Diagnostics (DGX) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$11.6B

Revenue (quarter)

$3.0B

Revenue growth (year over year)

+10.21%

Gross profit (trailing twelve months)

$3.8B

Gross margin

33.11%

Net income (trailing twelve months)

$1.1B

Net income (quarter)

$334.0M

Net income growth (year over year)

+12.84%

Net margin

9.63%

Return on equity

14.33%

EPS (trailing twelve months)

$9.54

Book value per share

$69.05

P/E (trailing twelve months)

24.85

Price to book

3.34

Debt to assets

53.37%

Payout ratio

35.41%

Dividend yield

1.41%

Company profile

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

• Is Quest Diagnostics (DGX) profitable?

  Yes. Quest Diagnostics earned $1.1B in net income over the trailing twelve months, a net margin of 9.63%.

• How much revenue does Quest Diagnostics (DGX) make?

  Quest Diagnostics generated $11.6B in revenue over the trailing twelve months, up 10.21% year over year.

• What is DGX's P/E ratio?

  Quest Diagnostics trades at 24.9 times trailing twelve-month earnings, on an EPS of $9.54.

• How do I buy stock in Quest Diagnostics (DGX)?

  DGX trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.